Werewolf Therapeutics, Inc.
HOWLNASDAQHealthcare● Active
$0.37
$-0.01(-1.86%)
Market Cap$18214081
P/E Ratio—
52W High$2.38
52W Low$0.37
Werewolf Therapeutics, Inc. (HOWL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HOWL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.28
Est. -$0.32 · +12.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
HOWL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.28 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.32 | -$0.28 | +12.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$0.34 | -$0.20 | +41.2% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.39 | -$0.36 | +7.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.50 | -$0.40 | +20.0% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.44 | -$0.40 | +9.1% | — | $0.00B | — |
| ▼ Q1 FY2025 | Mar 11, 2025 | -$0.43 | -$0.46 | -7.0% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.41 | -$0.38 | +7.3% | — | $0.00B | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.28
EPS Est.
-$0.32
EPS Surpr.
+12.5%
Revenue
—
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.34
EPS Surpr.
+41.2%
Revenue
—
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.39
EPS Surpr.
+7.7%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.50
EPS Surpr.
+20.0%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.44
EPS Surpr.
+9.1%
Revenue
—
Q1 FY2025
Mar 11, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.43
EPS Surpr.
-7.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.38
EPS Est.
-$0.41
EPS Surpr.
+7.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q3 FY2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Q2 FY2027 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q1 FY2027 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q4 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q3 FY2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +12.5% | $0.65 | $0.62 | -4.64% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +41.2% | $0.86 | $0.78 | -9.54% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +7.7% | $1.31 | $1.21 | -7.63% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +20.0% | $1.35 | $1.32 | -2.22% |
| ▲ Q2 FY2025 | May 8, 2025 | +9.1% | $0.92 | $0.87 | -5.54% |
| ▼ Q1 FY2025 | Mar 11, 2025 | -7.0% | $1.23 | $1.26 | +2.44% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +7.3% | $2.44 | $2.24 | -8.20% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -5.3% | $1.71 | $1.85 | +8.19% |
Q2 FY2026-4.64%
Report Date
May 7, 2026
EPS Beat/Miss
+12.5%
Price Before
$0.65
Price After
$0.62
Q1 FY2026-9.54%
Report Date
Mar 27, 2026
EPS Beat/Miss
+41.2%
Price Before
$0.86
Price After
$0.78
Q4 FY2025-7.63%
Report Date
Nov 4, 2025
EPS Beat/Miss
+7.7%
Price Before
$1.31
Price After
$1.21
Q3 FY2025-2.22%
Report Date
Aug 14, 2025
EPS Beat/Miss
+20.0%
Price Before
$1.35
Price After
$1.32
Q2 FY2025-5.54%
Report Date
May 8, 2025
EPS Beat/Miss
+9.1%
Price Before
$0.92
Price After
$0.87
Q1 FY2025+2.44%
Report Date
Mar 11, 2025
EPS Beat/Miss
-7.0%
Price Before
$1.23
Price After
$1.26
Q4 FY2024-8.20%
Report Date
Nov 7, 2024
EPS Beat/Miss
+7.3%
Price Before
$2.44
Price After
$2.24
Q3 FY2024+8.19%
Report Date
Aug 8, 2024
EPS Beat/Miss
-5.3%
Price Before
$1.71
Price After
$1.85
Avg Beat Reaction-6.29%
Avg Miss Reaction+5.31%
Beat Rate6 / 8 quarters
Largest Move-9.54% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HOWL ends December
Werewolf Therapeutics, Inc. (HOWL) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.28 — beating the analyst consensus of $-0.32 by +12.5%. HOWL has beaten EPS estimates for 5 consecutive quarters. The next HOWL earnings date is expected around September 1, 2026.
Each quarter, investors track HOWL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HOWL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HOWL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HOWL earnings · 5 questionsWerewolf Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. HOWL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HOWL historically reports after market close (AMC).
HOWL earnings datewhen is HOWL earningsHOWL next earnings datewhen does HOWL report earningsHOWL earnings calendar
▸ Source: FMP · Werewolf Therapeutics, Inc. SEC filings · US GAAP · Werewolf Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026